Aligos Therapeutics (ALGS) vs BriaCell Therapeutics (BCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aligos Therapeutics (ALGS) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 46.5% versus a loss of 69.2%. Over five years, BCTX leads with a -95.2% price change compared with -98.7% for ALGS. BriaCell Therapeutics is the larger company by market cap ($34.1 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | BCTX |
|---|---|---|
| Share price | $5.31 | $3.92 |
| Market cap | $33.16M | $34.10M |
| 1-day change | -0.19% | -2.00% |
| YTD return | -43.03% | -44.87% |
| 1-year return | -46.53% | -69.18% |
| 5-year return | -98.66% | -95.21% |
| EPS (TTM) | $-7.41 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $14.68 |
| 52-week low | $3.98 | $2.60 |
| Distance from 52-week high | -61.21% | -73.30% |
| Analyst consensus | none | — |
| Avg. price target upside | +886.44% | — |
| Average volume | 88.98K | 278.91K |
| Shares outstanding | 5.44M | 8.70M |
| Employees | 82 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALGS has outperformed BCTX by 22.7 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Healthcare · Biotechnology · 82 employees
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Healthcare · Biotechnology
ALGS vs BCTX FAQ
Which is bigger, Aligos Therapeutics or BriaCell Therapeutics?
BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $34.10M compared with $33.16M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or BCTX?
ALGS returned -46.53% over the past 12 months, compared with -69.18% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and BriaCell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.